<DOC>
	<DOC>NCT01759472</DOC>
	<brief_summary>To determine whether LTD4-BPT could be an effective indicator for predicting efficacy of anti-leukotriene therapy, allowing objective proofs for the use of LTRA among asthmatics in a specific sensitive to leukotriene population of asthma. Hypothesis ：Monteluakst can better improve pre-challenge FEV1 from baseline in leukotriene-sensitive group than leukotriene-insensitive group.</brief_summary>
	<brief_title>Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Leukotriene Antagonists</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>1. Aged 1560 years, male or female. 2. Mild to moderate persistent asthma. 3. Mini AQLQ score ≤6 or ACQ score ≥1. 4. Giving written informed consent. 1. Current smoker or quitted smoking ≤12 months. 2. Significant allergen exposure. 3. Respiratory tract infection within 2 weeks before or during the study. 4. Cardiovascular disease. 5. History of malignant disease within the preceding 5 years. 6. And/or concomitant pulmonary disease. 7. Pregnant or breastfeed period. 8. Use of leukotrienes receptor antagonist within 5 days</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>leukotriene</keyword>
	<keyword>leukotriene receptor antagonist</keyword>
</DOC>